Biomarkers for glaucoma: from the lab to the clinic

Area of Science:

• Ophthalmology
• Neuroscience
• Immunology

Background:

• Glaucoma is a leading cause of irreversible blindness, often diagnosed late due to a lack of early, objective diagnostic measures.
• Elevated intraocular pressure (IOP) is a primary risk factor, but age, sex, ethnicity, oxidative stress, glutamate, and autoimmunity also influence disease progression.

Purpose of the Study:

• To identify potential proteomic biomarkers for glaucoma.
• To investigate the role of autoantibodies in glaucoma pathogenesis and their potential as diagnostic markers.

Main Methods:

• Analysis of the human retina proteome in glaucoma patients.
• Utilizing experimental autoimmune glaucoma (EAG) and intermittent IOP elevation animal models.
• In vivo studies on neuroretinal cells and porcine retinal explants.

Main Results:

• Demonstrated IOP-independent retinal ganglion cell (RGC) loss in an EAG model, associated with antibody depositions and microglia activation.
• Showed that intermittent IOP elevations cause neurodegeneration and alter IgG autoantibody reactivities.
• Identified a protective effect of certain antibodies (e.g., anti-GFAP) on RGCs, potentially by reducing retinal stress.

Conclusions:

• Autoantibody profiling shows promise as a biomarker for glaucoma diagnosis, progression, and severity.
• The absence of specific autoantibodies in glaucoma patients may signify a loss of natural protective autoimmunity, potentially promoting neurodegeneration.
• Future longitudinal studies are crucial for improving early detection and disease monitoring.